Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907838 | 0.92 | KMT2A (0.73) | KMT2AMEN1POLBSMN1; SMN2TSHR | |
| SCHEMBL7987656 | 0.88 | LTB4R (0.66) | KMT2AMEN1POLBSMN1; SMN2LTB4R | |
| SCHEMBL7994027 | 0.88 | LTB4R (0.66) | KMT2AMEN1POLBSMN1; SMN2LTB4R | |
| SCHEMBL7990328 | 0.86 | KMT2A (0.50) | KMT2AMEN1PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL3014488 | 0.86 | PTGDR2 (0.53) | KMT2AMEN1PTGDR2CREBBP | |
| SCHEMBL7566116 | 0.85 | PTGDR2 (0.63) | KMT2AMEN1PTGDR2CREBBP | |
| SCHEMBL5533467 | 0.85 | FFAR1 (0.52) | KMT2AMEN1PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL7976117 | 0.84 | LTB4R (0.69) | KMT2AMEN1PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL7361563 | 0.83 | KMT2A (0.65) | KMT2AMEN1SMN1; SMN2CREBBPALDH1A1 | |
| SCHEMBL7987686 | 0.83 | KMT2A (0.45) | KMT2AMEN1PTGDR2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070189970-A1 | Contrast medium for thrombus formation | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-0691959-B1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070189970-A1 | Contrast medium for thrombus formation | FGB, F13B, TFPI | KMT2A 4821/4885MEN1 920/4885PTGDR2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.